Skip to main content

Table 2 Primary clinical endpoint (combination of death, MI and TVR)

From: Bioresorbable scaffold implantation in STEMI patients: 5 years imaging subanalysis of PRAGUE-19 study

 At 5 years FU (N = 79)Years 1–5 (N = 77)
Primary clinical endpoint, n (%)10 (12.6%)3 (3,9%)
Death, n (%)5 (6.3%)3 (3.9%)
Cardiovascular (sudden death at 14 days, 9 and 51 months), n (%)3 (3.8%)1 (1.3%)
Non-cardiac (cancer at 40 months and 50 months), n (%)2 (2.5%)2 (2.6%)
Myocardial infarction, n (%)2 (2.5%)0 (0%)
Target vessel revascularization, n (%)3 (3.8%)0 (0%)
BRS thrombosis definite/probable, n (%)2 (2.5%)0 (0%)
  1. MI myocardial infarction, TVR target vessel revascularization, FU follow-up, BRS bioresorbable scaffold